Comerica Securities’s Genmab GMAB Stock Holding History

Comerica Securities’s Portfolio GMAB Stock Details GMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-2,248	Closed	-$95.3K	–	845
2022 Q4	$95.3K	Buy	+2,248	New	+$92.6K	0.01%	603

Other funds holding GMAB

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

1832 Asset Management Toronto, Ontario, Canada $109B AUM 35.56% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Comerica Securities's GMAB Position: Q1 2023 in Review

Comerica Securities sold out of Genmab (GMAB) in Q1 2023, closing a stake of 2,248 shares — an estimated $95.3K sold.

Comerica Securities first reported a position in GMAB in Q4 2022 and held it in 1 quarter. The position peaked at $95.3K in Q4 2022. 216 funds tracked by Wall St. Rank hold GMAB as of Q1 2023.

Comerica Securities reported no remaining Genmab position as of Q1 2023 after selling out during the quarter.
Comerica Securities sold 2,248 Genmab shares in Q1 2023, an estimated $95.3K.
Comerica Securities first reported a position in Genmab in Q4 2022 and held it in 1 quarter.
Comerica Securities's Genmab position peaked at $95.3K in Q4 2022.
216 funds tracked by Wall St. Rank held Genmab as of Q1 2023.

Based on Comerica Securities's 13F filing for Q1 2023, filed 27 Apr 2023.